Dapagliflozin combined with liraglutide for the treatment of type 2 diabetes mellitus complicated by chronic heart failure in 90 patients
10.3760/cma.j.issn.1008-6706.2022.01.015
- VernacularTitle:达格列净联合利拉鲁肽治疗2型糖尿病合并慢性心力衰竭患者90例
- Author:
Binli ZHONG
1
;
Yan ZHANG
Author Information
1. 厦门大学附属第一医院思明院区内科，厦门 361000
- Keywords:
Diabetes mellitus,type 2;
Heart failure;
Drug therapy,combination;
Dapagliflozin;
Liraglutide;
Blood glucose;
Glycated hemoglobin |glycosylated hemoglobin;
H
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(1):73-76
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of dapagliflozin combined with liraglutide in the treatment of type 2 diabetes mellitus complicated by chronic heart failure.Methods:Ninety patients with type 2 diabetes mellitus complicated by chronic heart failure, who received treatment in the Siming Branch of the First Affiliated Hospital of Xiamen University from August 2018 to August 2020, were included in this study. They were randomly assigned to receive either routine treatment + liraglutide (control group, n = 45) or routine treatment + liraglutide + dapagliflozin (observation group, n = 45) for 16 weeks. Blood glucose control, glycosylated hemoglobin level, cardiac function grade, serum N-terminal B-type natriuretic peptide precursor level, left ventricular ejection fraction, total effective rate, and adverse reactions were compared between the control and observation groups before and after treatment. Results:There were no significant differences in blood glucose level, glycosylated hemoglobin, and cardiac function grade between the two groups (all P > 0.05) before treatment. After treatment, fasting blood glucose level, 2-hour postprandial glucose level, glycosylated hemoglobin level, cardiac function grade, N-terminal B-type natriuretic peptide precursor , and left ventricular ejection fraction were (7.21 ± 1.23) mmol/L, (9.14 ± 2.24) mmol/L, (7.03 ± 2.59)%, (1.25 ± 0.21), (548.9 ± 116.3) ng/L, and (46.7 ± 7.5)%, respectively, in the observation group and they were (9.45 ± 2.21) mmol/L, (11.24 ± 5.29) mmol/L, (8.23 ± 1.91)%, (2.23 ± 0.46), (510.3 ± 110.7) ng/L, and (48.1 ± 6.8)%, respectively in the control group. There were significant differences in these indexes between the two groups ( t = 24.03, 20.47, 51.09, 32.42, 10.19, 13.23, all P < 0.05). Total effective rate was significantly higher in the observation group than in the control group [97.78% (44/45) vs. 80.00% (36/45), χ2 = 7.20, P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusion:Dapagliflozin combined with liraglutide is highly effective in the treatment of type 2 diabetes mellitus complicated by chronic heart failure. The combined therapy has good effects on blood glucose level and cardiac function and is certainly safe.
